Good Review Management Guidance Splits Responsibility Between Sponsors & FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Final document decreases the draft's emphasis on pre-submission activities, noting that development is primarily sponsor's domain; submission shifts application management responsibility to FDA. Guidance outlines "model review management practices" and provides detailed links to relevant regulations.